Gilead says payers feel comfortable with the cost of Sovaldi

Eric Palmer As soon as Gilead Sciences named a price for its highly anticipated hep C drug Sovaldi, activists pounced–and payers showed some nervousness about laying out cash ...

Japan’s RegImmune nails down $9.2M to get its pipeline into the clinic

Damian Garde Tokyo drug developer RegImmune has banked $ 9.2 million in Series D financing to bankroll early-stage products using the company's immune system-regulating platform. FierceBiotech ...

GlaxoSmithKline eyes rare disease to widen its respiratory lead

Damian Garde GlaxoSmithKline is looking to deepen its respiratory pipeline with another late-stage trial of the injectable mepolizumab, this time studying the drug's effects in ...

Doxycycline sales power Hikma, but party may be ending

Eric Palmer Jordan-based Hikma has powered its growth with drugs on the FDA's shortage list such as doxycycline, sales of which have allowed the company to raise earnings projections ...

Isis, Biogen move forward on $300M antisense pact

Damian Garde Isis and partner Biogen Idec have kicked off a Phase II study of a spinal muscular atrophy treatment, part of the pair's $ 300 million alliance to advance antisense ...

Nestlé needs to leverage marketing power to beef up Galderma

Tracy Staton Nestlé has caught the dermatology fever sweeping through Big Pharma, as companies key in on the specialty sector's growth potential–and Nestlé pushes ...

Biotech IPOs roll on with Concert’s $84M aria

Damian Garde Lexington, MA's Concert Pharmaceuticals picked up $ 84 million in an upsized IPO, taking advantage of a prolonged boom for biotechs to replenish its R&D fund. FierceBiotech ...

Boehringer says it’s fighting 2,000 lawsuits over Pradaxa safety

Tracy Staton Pradaxa has become a bigger legal headache for Boehringer Ingelheim. The German drugmaker says it's facing more than 2,000 lawsuits in the U.S., filed by patients claiming ...

J&J, Pharmacyclics get CLL approval for Imbruvica

Eric Palmer Johnson & Johnson and Pharmacyclics' new drug Imbruvica won the expanded approval it needed to go beyond a rare disease treatment and reach the blockbuster status ...

FDA rejects Durect’s pitch to market post-operative pain therapy

John Carroll FierceBiotech News

Third Rock puts up $45M for a voyage into gene therapy

Damian Garde Third Rock Ventures has cut the ribbon on its latest startup, pledging $ 45 million to launch Cambridge, MA's Voyager Therapeutics, a gene therapy biotech with a promising ...

UPDATED: FDA panel says Aleve should keep its heart-risk warning

Eric Palmer Bayer's painkiller Aleve carries the same heart-risk warning as other nonsteroidal anti-inflammatories, or NSAIDs, like Motrin and Advil. And as far as an FDA review ...
Page 2 of 3123
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS